VBL announces positive PhIII data for ovarian cancer drug; GeneCentric partners with Janssen on bladder cancer
VBL Therapeutics announced that it is on track in a Phase III trial of its drug VB-111 (ofranergene obadenovec) to treat …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
